Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.
临床前研究表明,Co-STARs 结合了嵌合抗原和 T 细胞受体的优势,可用于治疗抗原密度低的肿瘤
期刊:Science Translational Medicine
影响因子:14.6
doi:10.1126/scitranslmed.adg7123
Mog Brian J, Marcou Nikita, DiNapoli Sarah R, Pearlman Alexander H, Nichakawade Tushar D, Hwang Michael S, Douglass Jacqueline, Hsiue Emily Han-Chung, Glavaris Stephanie, Wright Katharine M, Konig Maximilian F, Paul Suman, Wyhs Nicolas, Ge Jiaxin, Miller Michelle S, Azurmendi P, Watson Evangeline, Pardoll Drew M, Gabelli Sandra B, Bettegowda Chetan, Papadopoulos Nickolas, Kinzler Kenneth W, Vogelstein Bert, Zhou Shibin
细胞生物学
肿瘤
T Cell Receptor
肿瘤免疫